Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeMD, Inc. filings document the formal disclosures for the virtual primary care company and its listed securities, including common stock and the 8.875% Series A Cumulative Perpetual Preferred Stock. Form 8-K reports cover operating results, financial condition, earnings guidance, Regulation FD investor presentations, and executive officer changes.
Definitive proxy materials describe annual meeting procedures, board and governance matters, compensation-related disclosures, and stockholder voting items. The filing record also identifies the preferred security within the company's capital structure, including matters relevant to LFMDP holders such as preferred-stock status and related public-company disclosures.
LifeMD, Inc. filed an initial insider ownership report on SEC Form 3 for Atul Kavthekar, who serves as Chief Financial Officer. The filing identifies him as a reporting person but shows no buy, sell, exercise, gift, tax-withholding, or other transactions, with all transaction counts and share totals at zero in this excerpt.
LifeMD, Inc. announced a planned Chief Financial Officer transition, with current CFO Marc Benathen departing to pursue a new opportunity and remaining through March 31, 2026 to support an orderly handover. He will then provide transition advisory services for six to twelve months for a $38,117 monthly fee and receive COBRA reimbursement through no later than April 1, 2027, while forfeiting any RSUs unvested as of March 31, 2026.
The company appointed Atul Kavthekar as its new CFO effective March 16, 2026, with a base salary of $500,000 and an annual performance bonus targeted at 50% of base salary. As a material employment inducement, he will receive 675,000 RSUs, split evenly between time-based vesting over three years and performance-based vesting tied to company targets.
LifeMD also expanded its leadership team by promoting Chris Pisano to Chief Marketing Officer and Jessica Friedeman to Chief Business Officer, reflecting a broader effort to align finance, marketing, and business development with the company’s next phase of growth.
LifeMD, Inc. reported strong 2025 growth, with full-year revenue up 25% to $194.1 million and adjusted EBITDA up 309% to $15.3 million. Fourth-quarter revenue rose 4% to $46.9 million, while adjusted EBITDA increased to $4.8 million, reflecting an 87% gross margin.
The business from continuing operations still posted a 2025 GAAP net loss of $10.2 million, but total net income reached $15.6 million including discontinued operations. LifeMD ended 2025 with $36.8 million in cash and no debt, supporting investment in GLP-1 weight management, Wegovy launches, and expanding women’s health offerings.
For 2026, LifeMD guides to revenue of $220–$230 million and adjusted EBITDA of $12–$17 million, with annualized run-rate revenue expected to exceed $250 million and run-rate adjusted EBITDA to exceed $25 million by Q4 2026.
Form 144 notice for proposed sale of securities. The filer intends to sell 75,000 common shares of the issuer through Charles Schwab (3000 Schwab Way, Westlake, TX) on 09/10/2025 on NASDAQ, with an aggregate market value of $459,000. The issuer has 47,417,393 shares outstanding. The 75,000 shares were acquired by RSU vesting from the issuer on 03/01/2025. No securities were sold by the selling person during the past three months. The notice includes the seller's representation that they possess no undisclosed material adverse information.
LifeMD insider stock award vested: The company's Chief Legal Officer and General Counsel, Eric H. Yecies, had a grant of 50,000 common shares vest on 08/22/2025. The report shows those shares were issued at a $0 per-share price as a performance-based award that vested.
Following this vested award the reporting person beneficially owns 388,900 shares of the issuer's common stock. The Form 4 discloses this as a non-derivative acquisition reflecting the conversion of a performance stock grant into common shares.
LifeMD, Inc. (LFMD) reporting person Dennis Wijnker, identified as an officer with the title Chief Technology Officer, reported a change in beneficial ownership on 08/22/2025. The Form 4 shows a grant of 25,000 shares of common stock that vested on that date with an acquisition price recorded as $0, described as performance stock. After the vesting, the reporting person beneficially owned 175,000 shares. The form is signed and dated 08/26/2025. The filing indicates this was a routine vesting event rather than an open-market purchase or sale.
Maria E. Stan, Chief Accounting Officer of LifeMD, Inc. (LFMD), reported a non‑derivative acquisition of common stock that vested on August 22, 2025. The Form 4 shows a grant of 20,000 shares was recorded as acquired at a price of $0 and the reporting person now beneficially owns 227,500 shares. The filing is signed and dated August 26, 2025. No other transactions or derivative positions are reported.
Insider filing shows grant vesting and holdings Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc. (LFMD), reported an acquisition on 08/22/2025 of 30,000 shares of common stock resulting from a performance stock grant that vested on that date. The reported price is $0, indicating these were shares issued on vesting rather than purchased. After the transaction, Galluppi directly beneficially owns 110,449 shares and indirectly beneficially owns 1,644,800 shares through American Nutra Tech, LLC. The Form 4 was signed on 08/26/2025.
LifeMD insider Jessica Friedeman acquired 50,000 shares of common stock upon vesting of performance stock on 08/22/2025. The Form 4 shows the transaction was reported on 08/26/2025 and lists Friedeman's role as Officer — Chief Marketing Officer. The filing reports 220,000 shares of common stock beneficially owned by the reporting person after the transaction. The acquisition is recorded as non‑derivative, with a reported price of $0 reflecting the vesting of previously granted performance stock.
LifeMD, Inc. reporting person Marc David Benathen, the company's Chief Financial Officer, had 87,000 shares of common stock become vested and were reported as acquired on 08/22/2025 at a reported price of $0, described as performance stock that vested. Following the transaction he beneficially owns 426,554 shares. The Form 4 is filed individually by the reporting person and lists the reporting person's address as LifeMD, Inc., 236 Fifth Avenue, Suite 400, New York, NY 10001.